These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Neoadjuvant hormonal therapy for prostate cancer].
    Author: Miyakita H.
    Journal: Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984.
    Abstract:
    Preoperative neoadjuvant hormonal therapy is still controversial. This therapy's purpose is downstaging prostate cancer at radical prostatectomy and thereby improving the prognosis of prostate cancer. It has been repeatedly demonstrated that hormonal therapy causes significant alterations in the gross and microscopic appearance of the prostate. Most studies report a significant improvement in surgical margins and downstaging. However, it remains to be seen if the favorable findings lead to an improved outcome after radical prostatectomy. Our study showed 6-12 months neoadjuvant hormonal therapy with maximal androgen blockade did not lead to the improved result in long term follow-up. Because, PSA failure was observed 25% of the cases which received neoadjuvant hormonal therapy prior to radical prostatectomy.
    [Abstract] [Full Text] [Related] [New Search]